The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the ...

The efficacy of ropeginterferon alfa-2b was limited in patients with myelofibrosis, especially if they had mutations at high-molecular risk.

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Polycythemia vera results from an acquired genetic mutation rather than an inherited one. Learn more.

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...